

U.S. Serial No. 09/966,202

Attorney Docket R0086B-DIV

**Listing of Claims**

1. (Original) A method of treating emphysema in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof.
- 2-5 (canceled)
6. (original) The method of Claim 1, wherein the therapeutically effective amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof, repairs alveoli in the mammal.
7. (original) The method of Claim 1, wherein the mammal is human.
8. (original) The method of Claim 7, wherein the human was or is a cigarette smoker.
9. (original) The method of Claim 1, wherein the emphysema is panlobar emphysema, centrilobular emphysema or distal lobular emphysema.
10. (original) The method of Claim 1, wherein the therapeutically effective amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof is administered with an electrohydrodynamic aerosol device.
11. (previously amended) A pharmaceutical composition suitable for treating a mammal suffering from emphysema comprising an amount of 13-*cis*-retinoic acid or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof and a pharmaceutically acceptable carrier, said amount being sufficient to alleviate at least one symptom of emphysema.
12. (previously amended) The pharmaceutical composition of Claim 36, wherein the pharmaceutically acceptable carrier is suitable for electrohydrodynamic aerosol device, a aerosol device or a nebulizer device.
13. (previously amended) The pharmaceutical composition of Claim 36, wherein the amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof, is between about 0.1 µg and about 10.0 mg.

U.S. Serial No. 09/966,202

Attorney Docket R0086B-DIV

14. (original) The pharmaceutical composition of Claim 13, wherein the amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof, is between about 1.0 µg and about 1.0 mg.
15. (original) The pharmaceutical composition of Claim 14 wherein the amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof is between about 100.0 µg and about 300.0 µg.
16. (original) The pharmaceutical composition of Claim 12, wherein the pharmaceutically acceptable carrier is a liquid.
17. (original) The pharmaceutical composition of Claim 16, wherein the pharmaceutically acceptable carrier is chosen from the group consisting of water, alcohol and perfluorocarbon.
18. (original) The pharmaceutical composition of Claim 16, wherein the amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof is between about 1.0 µg and about 100.0 µg.
19. (original) The pharmaceutical composition of Claim 18, wherein the amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof is between about 3.0 µg and about 30.0 µg.
20. (original) The pharmaceutical composition of Claim 19, wherein the amount of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof is between about 5.0 µg and about 15.0 µg.
21. (original) The method of Claim 9, wherein the mammal is human.
22. (original) The method of Claim 21, wherein the human was or is a cigarette smoker.
23. (previously amended) The composition of Claim 11, wherein the emphysema is panlobar emphysema, centrilobular emphysema or distal lobular emphysema.

24. (original) A method for treating emphysema and related disorders comprising delivering a formulation of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof, into the lungs of a mammal.
25. (original) The method of Claim 24, wherein the emphysema is panlobar emphysema, centrilobular emphysema or distal lobular emphysema
26. (original) The method of Claim 25, wherein the mammal is human.
27. (original) The method of Claim 26, wherein the human was or is a cigarette smoker.
28. (original) The method of Claim 24, wherein the formulation is delivered into the lungs of the mammal with a nebulizer device.
29. (previously amended) The method for treating emphysema and related disorders comprising delivering a formulation of 13-*cis*-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof, into the lungs of the mammal with an aerosol device.
30. (previously amended) The method of Claim 29, wherein the formulation is delivered into the lungs of the mammal with an electrohydrodynamic aerosol device.
31. (original) A method for treating emphysema comprising combining the use of 13-*cis*-retinoic acid with one or more additional therapies.
32. (original) The method of Claim 31, wherein the additional therapies are chosen from the group consisting of smoking cessation, bronchodilators, antibiotics and oxygen therapy.
- 33-35 (canceled)
36. (previously added) A pharmaceutical composition according to claim 11 wherein the pharmaceutical composition is suitable for administration to the lungs by inhalation.
- 37-42. (canceled)

43. (previously added) The pharmaceutical composition of Claim 36, wherein said form is suitable for administration through a dry powder inhaler.
44. (previously added) The pharmaceutical composition of Claim 36 wherein said form is suitable for administration through a liquid spray device.
45. (previously added) The pharmaceutical composition of Claims 44, wherein said liquid spray device is an aerosol device.
46. (previously added) The pharmaceutical composition of Claim 45, wherein said aerosol device is a nebulizer or electrohydrodynamic aerosol device.
47. (canceled).

\* \* \* \* \*